• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

    2/20/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email

    SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2024.

    Fourth Quarter 2024 Financial Highlights

    • Revenue of $164.3 million, a 24.0% increase compared to fourth quarter 2023
    • Gross margin of 70.0%, a 410-basis point increase compared to fourth quarter 2023
    • Net loss of $1.3 million, a $37.4 million improvement compared to fourth quarter 2023
    • Adjusted EBITDA of $19.3 million, a $16.9 million improvement compared to fourth quarter 2023
    • Cash, cash equivalents and marketable securities of $535.6 million at December 31, 2024, a $13.6 million increase from September 30, 2024

    Full Year 2024 Financial Highlights

    • Revenue of $591.8 million, a 20.1% increase compared to full year 2023
    • Gross margin of 68.9%, a 160-basis point increase compared to full year 2023
    • Net loss of $113.3 million, a $10.1 million improvement compared to full year 2023
    • Adjusted EBITDA of $(7.7) million, a decline of $2.9 million compared to full year 2023

    Recent Operational Highlights

    • Fourth quarter 2024 capped a year of progressively accelerating year-over-year volume growth every quarter, with full year 2024 revenue driven by sustained volume demand across all customer channels
    • Analysis of real-world claims data conducted by Eversana and presented at AHA in November 2024 suggested that early detection with arrhythmia monitoring devices could have the combined potential to help prevent serious outcomes like stroke and heart failure while also significantly reducing acute care utilization and related costs in patients with type 2 diabetes and chronic obstructive pulmonary disease
    • Upcoming data presentations at the American College of Cardiology's Annual Scientific Session & Expo in Chicago, IL, from March 29 – 31, 2025

    "Our fourth quarter capped a transformative year for iRhythm, marked by 24% revenue growth and significant operational achievements," said Quentin Blackford, President and CEO of iRhythm. "We achieved record new account onboarding, with balanced volume contributions across multiple channels, particularly in risk-bearing, primary care settings where Zio's value as a population health management tool has resonated strongly. Throughout 2024, we enhanced our quality systems, improved customer experience through EHR integration and innovative product launches, expanded into multiple international markets, and secured strategic technology licensing agreements to advance connected patient care. Our commitment to operational discipline has yielded positive cash flow for three consecutive quarters, while our extensive scientific publications have further validated our approach. Looking ahead, we remain focused on delivering a best-in-class quality system while creating shareholder value through our strategies of expanding our core U.S. market presence, accelerating international growth, advancing product innovation, and further advancing operational efficiencies. As we scale the Zio platform globally, we're uniquely positioned to shape the future of healthcare while driving value for patients, physicians, health systems, and shareholders."

    Fourth Quarter 2024 Financial Results

    Revenue for the three months ended December 31, 2024, increased 24.0% to $164.3 million, from $132.5 million during the same period in 2023. The increase was primarily attributable to increases in the volume of Zio Services resulting from increased demand, partially offset by a slight decline in average selling price.

    Gross profit for the fourth quarter of 2024 was $115.1 million, up from $87.4 million during the same period in 2023, while gross margins were 70.0% as compared to 66.0% during the same period in 2023. The improvement in gross margin was primarily driven by operational efficiencies leading to lower costs per unit to serve a higher volume of patients compared to the prior year.

    Operating expenses for the fourth quarter of 2024 were $119.2 million, compared to $126.6 million for the same period in 2023 and $151.8 million in the third quarter of 2024. The fourth quarter of 2023 included $11.1 million of higher operating expenses due to an impairment charge for our right-of-use capitalized leased asset value of our San Francisco office. The decrease in operating expenses compared to the third quarter 2024 was due primarily to a $32.1 million charge in the third quarter of 2024 for in-process research and development charges related to technology license consideration.

    Net loss for the fourth quarter of 2024 was $1.3 million, or a diluted loss of $0.04 per share, compared with net loss of $38.7 million, or a diluted loss of $1.26 per share, for the same period in 2023.

    Full Year 2024 Financial Results

    Revenue for the year ended December 31, 2024, increased 20.1% to $591.8 million, from $492.7 million in 2023. The increase in revenue was primarily due to increased volume of Zio services provided as a result of increased demand.

    Gross profit for the year was $407.5 million, up from $331.8 million in 2023, while gross margin was 68.9%, an improvement from 67.3% in 2023. The improvement in gross margin was primarily driven by operational efficiencies leading to lower costs per unit to serve a higher volume of patients compared to the prior year.

    Operating expenses for the year were $523.0 million, an increase of 14.5% compared to 2023. The increase was mainly due to acquired IPR&D expenses related to license consideration, along with an increase in headcount-related costs and professional fees to support the growth in our business.

    Net loss for 2024 was $113.3 million, or a diluted loss of $3.63 per share, compared with net loss of $123.4 million, or a diluted loss of $4.04 per share in 2023.

    Cash, cash equivalents and marketable securities were $535.6 million as of December 31, 2024.

    2025 Guidance

    iRhythm projects revenue for the full year 2025 between $675 million to $685 million. Adjusted EBITDA margin for the full year 2025 is expected to range from approximately 7.0% to 8.0% of revenues.

    Webcast and Conference Call Information

    iRhythm's management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event, which will be available on the investors section of the Company's website at investors.irhythmtech.com.

    About iRhythm Technologies, Inc.

    iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all.

    Use of Non-GAAP Financial Measures

    We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted net loss, adjusted net loss per share and adjusted operating expenses. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted operating expenses and adjusted EBITDA estimates for full year 2025 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted operating expenses and adjusted EBITDA estimates is not available without unreasonable effort.

    Adjusted EBITDA excludes non-cash operating charges for stock-based compensation expense, changes in fair value of strategic investments, impairment and restructuring charges, business transformation costs, and loss on extinguishment of debt. Business transformation costs include costs associated with professional services, employee termination and relocation, third-party merger and acquisition, integration, and other costs to augment and restructure the organization, inclusive of both outsourced and offshore resources.

    Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate', ‘estimate', ‘expect', ‘intend', ‘will', ‘project', ‘plan', ‘believe', ‘target' and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular these statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, international market expansion, anticipated productivity and quality improvements, and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled "Risk Factors" and elsewhere in our filings made with the Securities and Exchange Commission, including those on the Form 10-K expected to be filed on or about February 20, 2025. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

    Investor Contact

    Stephanie Zhadkevich

    [email protected]

    Media Contact

    Kassandra Perry

    [email protected]



    IRHYTHM TECHNOLOGIES, INC.

    Consolidated Balance Sheets

    (In thousands, except par value)
     
     December 31,
      2024   2023 
    Assets   
    Current assets:   
    Cash and cash equivalents$419,597  $36,173 
    Marketable securities 115,956   97,591 
    Accounts receivable, net 79,941   61,484 
    Inventory 14,039   13,973 
    Prepaid expenses and other current assets 16,286   21,591 
    Total current assets 645,819   230,812 
    Property and equipment, net 125,092   104,114 
    Operating lease right-of-use assets 47,564   49,317 
    Restricted cash 8,358   — 
    Goodwill 862   862 
    Long-term strategic investments 61,902   3,000 
    Other assets 41,852   45,039 
    Total assets$931,449  $433,144 
    Liabilities and Stockholders' Equity   
    Current liabilities:   
    Accounts payable$7,221  $5,543 
    Accrued liabilities 84,900   83,362 
    Deferred revenue 2,932   3,306 
    Operating lease liabilities, current portion 15,867   15,159 
    Total current liabilities 110,920   107,370 
    Long-term senior convertible notes 646,443   — 
    Debt, noncurrent portion —   34,950 
    Other noncurrent liabilities 8,579   1,012 
    Operating lease liabilities, noncurrent portion 74,599   79,715 
    Total liabilities 840,541   223,047 
    Stockholders' equity:   
    Preferred stock, $0.001 par value – 5,000 shares authorized; none issued and outstanding at December 31, 2024 and 2023 —   — 
    Common stock, $0.001 par value – 100,000 shares authorized; 31,621 shares issued and 31,392 shares outstanding at December 31, 2024, respectively; and 30,954 shares issued and outstanding at December 31, 2023 31   31 
    Additional paid-in capital 874,607   855,784 
    Accumulated other comprehensive income (loss) 165   (112)
    Accumulated deficit (758,895)  (645,606)
    Treasury stock, at cost; 229 and 0 shares at December 31, 2024 and 2023, respectively (25,000)  — 
    Total stockholders' equity 90,908   210,097 
    Total liabilities and stockholders' equity$931,449  $433,144 
        





    IRHYTHM TECHNOLOGIES, INC.

    Consolidated Statements of Operations

    (In thousands, except per share data)
     
     (Unaudited)

    Three Months Ended December 31,
     Year Ended December 31,
      2024   2023   2024   2023 
    Revenue, net$164,325  $132,511  $591,839  $492,681 
    Cost of revenue 49,257   45,085   184,308   160,875 
    Gross profit 115,068   87,426   407,531   331,806 
    Operating expenses:       
    Research and development 19,081   15,416   71,459   60,244 
    Acquired in-process research and development 302   —   32,371   — 
    Selling, general and administrative 99,768   100,114   418,565   385,645 
    Impairment and restructuring charges —   11,078   641   11,078 
    Total operating expenses 119,151   126,608   523,036   456,967 
    Loss from operations (4,083)  (39,182)  (115,505)  (125,161)
    Interest and other income (expense), net:       
    Interest income 5,740   1,734   21,938   6,353 
    Interest expense (3,320)  (941)  (12,821)  (3,650)
    Loss on extinguishment of debt —   —   (7,589)  — 
    Other income (expense), net 481   (55)  1,253   (198)
    Total interest and other income (expense), net 2,901   738   2,781   2,505 
    Loss before income taxes (1,182)  (38,444)  (112,724)  (122,656)
    Income tax provision 151   255   565   750 
    Net loss$(1,333) $(38,699) $(113,289) $(123,406)
    Net loss per common share, basic and diluted$(0.04) $(1.26) $(3.63) $(4.04)
    Weighted-average shares, basic and diluted 31,343   30,702   31,196   30,528 





    IRHYTHM TECHNOLOGIES, INC.

    Reconciliation of GAAP to Non-GAAP Financial Information

    (In thousands, except per share data)

    (Unaudited)
     
     Three Months Ended December 31, Year Ended December 31,
      2024   2023   2024   2023 
    Adjusted EBITDA reconciliation*       
    Net loss1$(1,333) $(38,699) $(113,289) $(123,406)
    Interest expense 3,320   941   12,821   3,650 
    Interest income (5,740)  (1,734)  (21,938)  (6,353)
    Changes in fair value of strategic investments (843)  —   (1,902)  — 
    Income tax provision 151   255   565   750 
    Depreciation and amortization 5,289   4,914   20,715   16,348 
    Stock-based compensation 16,008   23,846   75,978   77,204 
    Impairment charges —   11,078   641   11,078 
    Business transformation costs 2,416   1,772   11,072   15,866 
    Loss on extinguishment of debt —   —   7,589   — 
    Adjusted EBITDA$19,268  $2,373  $(7,748) $(4,863)
            
    *Certain numbers expressed may not sum due to rounding.

    1Net loss for the three and twelve months ended December 31, 2024, includes acquired in-process research and development expense of $0.3 million and $32.4 million, respectively.



    Adjusted net income (loss) reconciliation*       
    Net loss, as reported1$(1,333) $(38,699) $(113,289) $(123,406)
    Impairment charges —   11,078   641   11,078 
    Business transformation costs 2,416   1,772   11,072   15,866 
    Changes in fair value of strategic investments (843)  —   (1,902)  — 
    Loss on extinguishment of debt —   —   7,589   — 
    Adjusted net income (loss)$240  $(25,849) $(95,889) $(96,462)
            
    Adjusted net income (loss) per share reconciliation:*       
    Diluted net loss per share, as reported1$(0.04) $(1.26) $(3.63) $(4.04)
    Impairment charges per share —   0.36   0.02   0.36 
    Business transformation costs per share 0.08   0.06   0.35   0.52 
    Changes in fair value of strategic investments per share (0.03)  —   (0.06)  — 
    Loss on extinguishment of debt per share —   —   0.24   — 
    Adjusted diluted net income (loss) per share$0.01  $(0.84) $(3.08) $(3.16)
            
    Weighted-average shares, basic 31,343   30,702   31,196   30,528 
    Weighted-average shares, diluted 31,710   30,702   31,196   30,528 
            
    Adjusted operating expenses reconciliation*       
    Operating expenses, as reported$119,151  $126,608  $523,036  $456,967 
    Impairment charges —   (11,078)  (641)  (11,078)
    Business transformation costs (2,416)  (1,772)  (11,072)  (15,866)
    Adjusted operating expenses$116,735  $113,758  $511,323  $430,023 
     
    *Certain numbers expressed may not sum due to rounding.

    1Net loss for the three and twelve months ended December 31, 2024, includes acquired in-process research and development expense of $0.3 million and $32.4 million, respectively.





    Primary Logo

    Get the next $IRTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRTC

    DatePrice TargetRatingAnalyst
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    12/3/2024$86.00Equal Weight
    Wells Fargo
    10/4/2024$78.00Neutral
    Goldman
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    12/11/2023$110.00Neutral → Buy
    Citigroup
    7/19/2023$130.00Outperform
    Robert W. Baird
    2/7/2023$150.00Overweight
    Wells Fargo
    11/7/2022Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $IRTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      11/5/24 11:59:44 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      8/5/24 5:35:18 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

      4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)

      12/6/23 7:08:38 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yoor Brian B was granted 1,358 shares, increasing direct ownership by 32% to 5,598 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      5/29/25 4:06:28 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Director Snyderman Ralph was granted 1,358 shares, increasing direct ownership by 11% to 13,288 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      5/29/25 4:04:54 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Director Bodaken Bruce G. was granted 1,358 shares, increasing direct ownership by 12% to 12,638 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      5/29/25 4:05:39 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iRhythm Technologies to Participate in Upcoming Investor Conferences

      SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025, at 2:00 p.m. Central Time (12:00 p.m. Pacific Time)Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. Eastern Time (11:40 a.m. Pacific Time)Truist Securities MedTech Conference on Tuesday, June 17, 2025, at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time) Inter

      5/21/25 4:45:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection

      iRhythm Zio® Long-Term Continuous Monitoring (LTCM) system — commercially introduced in Japan as the Zio® ECG Recording and Analysis System — brings AI-powered, continuous, uninterrupted ECG monitoring for up to 14 days to JapanLaunch is timely amid a growing demand for early, accurate detection of arrhythmias in Japan, the second largest ambulatory cardiac monitoring market in the world, where the prevalence is expected to rise alongside an aging population1-3 SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio® long-term continuous ECG monitoring (LTCM) system, commercially introduced in thi

      5/1/25 4:10:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Announces First Quarter 2025 Financial Results

      SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu

      5/1/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

      SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      11/12/24 12:54:21 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

      SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      11/12/24 9:52:49 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

      SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      11/7/24 4:05:49 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    SEC Filings

    See more
    • iRhythm Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - iRhythm Technologies, Inc. (0001388658) (Filer)

      5/30/25 4:01:53 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by iRhythm Technologies Inc.

      SD - iRhythm Technologies, Inc. (0001388658) (Filer)

      5/21/25 4:02:02 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by iRhythm Technologies Inc.

      SCHEDULE 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      5/13/25 11:32:29 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • iRhythm upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00

      5/2/25 8:03:46 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Wells Fargo resumed coverage on iRhythm with a new price target

      Wells Fargo resumed coverage of iRhythm with a rating of Equal Weight and set a new price target of $86.00

      12/3/24 7:33:58 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on iRhythm with a new price target

      Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00

      10/4/24 7:40:56 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Financials

    Live finance-specific insights

    See more
    • iRhythm Technologies Announces First Quarter 2025 Financial Results

      SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu

      5/1/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 1, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading di

      4/17/25 4:30:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

      SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue of $164.3 million, a 24.0% increase compared to fourth quarter 2023Gross margin of 70.0%, a 410-basis point increase compared to fourth quarter 2023Net loss of $1.3 million, a $37.4 million improvement compared to fourth quarter 2023Adjusted EBITDA of $19.3 million, a $16.9 million improvement compared to fourth quarter 2023Cash, cash equ

      2/20/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Leadership Updates

    Live Leadership Updates

    See more
    • iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

      iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

      2/29/24 4:30:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Derrick Sung Joins Aerin Medical as Chief Financial Officer

      A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

      11/20/23 9:00:00 AM ET
      $IRTC
      $LUNG
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

      SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

      6/6/23 9:00:39 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care